Evidence map›Paper›PMID 27303390›Full record

ArticleFrontiers in microbiology2016

Induction of Protective Immunity against Toxoplasmosis in BALB/c Mice Vaccinated with Toxoplasma gondii Rhoptry-1.

Parthasarathy Sonaimuthu, Xiao T Ching, Mun Y Fong, Ramaswamy Kalyanasundaram, Yee L Lau

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Mining the Proteome ofAnimals : an open access journal from MDPI · 2022
    Review
  9. Nano vaccines forFrontiers in immunology · 2022
    Article
  10. Article
  11. Review
  12. Review
  13. Nano DNA Vaccine EncodingPharmaceutics · 2021
    Article
  14. Advances inVaccines · 2021
    Review
  15. RecombinantVaccines · 2021
    Article
  16. Protective Effect Against Toxoplasmosis inFrontiers in immunology · 2021
    Article
  17. Immunization With a DNA Vaccine Encoding theFrontiers in microbiology · 2021
    Article
  18. Article
  19. A Review on the Prevalence ofInternational journal of environmental research and public health · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Parthasarathy SonaimuthuDepartment of Parasitology, Faculty of Medicine, University of Malaya Kuala Lumpur, Malaysia.
Xiao T ChingDepartment of Parasitology, Faculty of Medicine, University of Malaya Kuala Lumpur, Malaysia.
Mun Y FongDepartment of Parasitology, Faculty of Medicine, University of Malaya Kuala Lumpur, Malaysia.
Ramaswamy KalyanasundaramDepartment of Biomedical Sciences, College of Medicine, University of Illinois at Chicago, Chicago IL, USA.
Yee L LauDepartment of Parasitology, Faculty of Medicine, University of Malaya Kuala Lumpur, Malaysia.
University of Malaya · MYUniversity of Illinois Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxoplasma gondii is the causative agent for toxoplasmosis. The rhoptry protein 1 (ROP1) is secreted by rhoptry, an apical secretory organelle of the parasite. ROP1 plays an important role in host cell invasion. In this study, the efficacy of ROP1 as a vaccine candidate against toxoplasmosis was evaluated through intramuscular or subcutaneous injection of BALB/c mice followed by immunological characterization (humoral- and cellular-mediated) and lethal challenge against virulent T. gondii RH strain in BALB/c mice. Briefly, a recombinant DNA plasmid (pVAX1-GFP-ROP1) was expressed in CHO cells while expression of recombinant ROP1 protein (rROP1) was carried out in Escherichia coli expression system. Immunization study involved injection of the recombinant pVAX1-ROP1 and purified rROP1 into different group of mice. Empty vector and PBS served as two different types of negative controls. Results obtained demonstrated that ROP1 is an immunogenic antigen that induced humoral immune response whereby detection of a protein band with expected size of 43 kDa was observed against vaccinated mice sera through western blot analysis. ROP1 antigen was shown to elicit cellular-mediated immunity as well whereby stimulated splenocytes with total lysate antigen (TLA) and rROP1 from pVAX1-ROP1 and rROP1-immunized mice, respectively, readily proliferated and secreted large amount of IFN-γ (712 ± 28.1 pg/ml and 1457 ± 31.19 pg/ml, respectively) and relatively low IL-4 level (94 ± 14.5 pg/ml and 186 ± 14.17 pg/ml, respectively). These phenomena suggested that Th1-favored immunity was being induced. Vaccination with ROP1 antigen was able to provide partial protection in the vaccinated mice against lethal challenge with virulent RH strain of tachyzoites. These findings proposed that the ROP1 antigen is a potential candidate for the development of vaccine against toxoplasmosis.

Indexed as

DNA plasmidrecombinant proteinROP1Toxoplasma gondiivaccine

Identifiers

PMID27303390
PMCPMC4883518
OpenAlexW2400666768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.